NEJM Evidence· 2022Q1

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan et al.

1,457citations
Q1SCImago
2022year

Short summary

The STRIDE regimen (a single priming dose of tremelimumab plus durvalumab) significantly improved overall survival by 15% compared to sorafenib in patients with unresectable hepatocellular carcinoma (16.43 vs. 13.77 months).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hepatology

HepatologyMedicine